The terms of the tentative approval mean the drug – categorised as a biosimilar in Europe but not in the US – is subject to an automatic stay of up to 30 months. Diabetes drug Basaglar ...
Basaglar is a long-acting insulin that may be available through Medicare Part D. If a person’s drug plan includes Basaglar, the plan cannot charge more than $35 per month. Basaglar is a brand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results